Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY, Wang GM, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, de Mel S, Koh LP, Tan LK, Ooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, Spencer A, Gopalakrishnan SK, Lu J, Chng WJ. Soekojo CY, et al. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470-e477. doi: 10.1016/j.clml.2019.04.011. Epub 2019 Apr 28. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31171473
Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.
de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, Donato LKS, Halim NAA, Mah J, Lim K, Poon LM, Tan B, Yelly, Lim HL, Koh LP, Tai BC, Chen Z, Chng WJ, Gopalakrishnan SK, Tan LK. de Mel S, et al. Among authors: ooi m. Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225-232. doi: 10.1016/j.hemonc.2018.04.001. Epub 2018 Apr 23. Hematol Oncol Stem Cell Ther. 2018. PMID: 29705566 Free article. Clinical Trial.
Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.
Guo M, Chan THM, Zhou Q, An O, Li Y, Song Y, Tan ZH, Ng VHE, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MGM, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chun CM, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG. Guo M, et al. Among authors: ooi mgm. Blood. 2023 Jun 22;141(25):3078-3090. doi: 10.1182/blood.2022015830. Blood. 2023. PMID: 36796022 Free article.
Risk Stratification in Multiple Myeloma.
Ooi MG, de Mel S, Chng WJ. Ooi MG, et al. Curr Hematol Malig Rep. 2016 Apr;11(2):137-47. doi: 10.1007/s11899-016-0307-4. Curr Hematol Malig Rep. 2016. PMID: 26883334 Review.
Immunotherapy in Multiple Myeloma.
Soekojo CY, Ooi M, de Mel S, Chng WJ. Soekojo CY, et al. Among authors: ooi m. Cells. 2020 Mar 3;9(3):601. doi: 10.3390/cells9030601. Cells. 2020. PMID: 32138182 Free PMC article. Review.
Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.
Girard LP, Soekojo CY, Ooi M, Chng WJ, de Mel S. Girard LP, et al. Among authors: ooi m. Front Oncol. 2022 Jun 9;12:905484. doi: 10.3389/fonc.2022.905484. eCollection 2022. Front Oncol. 2022. PMID: 35756635 Free PMC article. Review.
282 results